Pharmacologic therapy for the neurogenic bladder

Urologic Clinics of North America

Volumn 37, Issue 4, 2010, Pages 495-506

  Cameron, Anne P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Alpha adrenergic antagonist; Imipramine; Multiple sclerosis; Muscarinic antagonists; Neurogenic urinary bladder; Spinal cord injury

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DOXAZOSIN; DRONABINOL; FESOTERODINE; IMIPRAMINE; INDORAMIN; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PAROXETINE; PHENOXYBENZAMINE; PLACEBO; PRAZOSIN; PROPIVERINE; PURINERGIC P2X3 RECEPTOR; RESINIFERATOXIN; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ALZHEIMER DISEASE; BLADDER DISTENSION; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRY SKIN; EJACULATION; FATIGUE; FIRST PASS EFFECT; HEMATURIA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEMORY DISORDER; MUCOSAL DRYNESS; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NOCTURNAL ENURESIS; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TOXICITY; SPINAL CORD INJURY; URINARY URGENCY; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; URINARY BLADDER, NEUROGENIC;

EID: 77957930238     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2010.06.004     Document Type: Review

References (118)

1. Lemack G.E., Frohman E., Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology 2007, 69(5):893-897.
2. Fowler C.J., Panicker J.N., Drake M., et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80(5):470-477.
3. McGuire E.J., Woodside J.R., Borden T.A. Upper urinary tract deterioration in patients with myelodysplasia and detrusor hypertonia: a followup study. J Urol 1983, 129(4):823-826.
4. Weld K.J., Graney M.J., Dmochowski R.R. Differences in bladder compliance with time and associations of bladder management with compliance in spinal cord injured patients. J Urol 2000, 163(4):1228-1233.
5. Hebjorn S. Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparing methantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil). Urol Int 1977, 32(2-3):209-217.
6. Stohrer M., Murtz G., Kramer G., et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007, 51(1):235-242.
7. Amend B., Hennenlotter J., Schafer T., et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008, 53(5):1021-1028.
8. Kim Y.H., Bird E.T., Priebe M., et al. The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol 1997, 158(6):2083-2086.
9. Bschleipfer T., Schukowski K., Weidner W., et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 2007, 80(24-25):2303-2307.
10. Mansfield K.J., Chandran J.J., Vaux K.J., et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther 2009, 328(3):893-899.
11. Stohrer M., Blok B., Castro-Diaz D., et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009, 56:81-88.
12. Razdan S., Leboeuf L., Meinbach D.S., et al. Current practice patterns in the urologic surveillance and management of patients with spinal cord injury. Urology 2003, 61(5):893-896.
13. Nicholas R.S., Friede T., Hollis S., et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009, 1. CD004193.
14. Gajewski J.B., Awad S.A. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986, 135(5):966-968.
15. Horstmann M., Schaefer T., Aguilar Y., et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006, 25(5):441-445.
16. Van Kerrebroeck P.E., Amarenco G., Thuroff J.W., et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998, 17(5):499-512.
17. Bennett N., O'Leary M., Patel A.S., et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?. J Urol 2004, 171(2 Pt 1):749-751.
18. Caulfield M.P., Birdsall N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998, 50(2):279-290.
19. Wang P., Luthin G.R., Ruggieri M.R. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995, 273(2):959-966.
20. Levin R.M., Shofer F.S., Wein A.J. Cholinergic, adrenergic and purinergic response of sequential strips of rabbit urinary bladder. J Pharmacol Exp Ther 1980, 212(3):536-540.
21. Stevens L.A., Chapple C.R., Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol 2007, 52(2):531-538.
22. Braverman A.S., Luthin G.R., Ruggieri M.R. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998, 275(5 Pt 2):R1654-R1660.
23. Chess-Williams R., Chapple C.R., Yamanishi T., et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001, 21(5-6):243-248.
24. Matsui M., Motomura D., Karasawa H., et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A 2000, 97(17):9579-9584.
25. Ehlert F.J., Griffin M.T., Abe D.M., et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 2005, 313(1):368-378.
26. Tseng L.H., Chen I., Lin Y.H., et al. Genome-based expression profiling study following spinal cord injury in the rat: an array of 48-gene model. Neurourol Urodyn 2010, [Epub ahead of print].
27. Braverman A.S., Ruggieri M.R. Selective alkylation of rat urinary bladder muscarinic receptors with 4-DAMP mustard reveals a contractile function for the M2 muscarinic receptor. J Recept Signal Transduct Res 1999, 19(5):819-833.
28. Pontari M.A., Braverman A.S., Ruggieri M.R. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004, 286(5):R874-R880.
29. Novara G., Galfano A., Secco S., et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008, 54(4):740-763.
30. Kay G.G., Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008, 62(11):1792-1800.
31. Kay G.G., Granville L.J. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005, 27(1):127-138. quiz 139-40.
32. Kwon E.E., Prineas J.W. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994, 53(6):625-636.
33. Dietrich W.D., Prado R., Halley M., et al. Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats. J Neuropathol Exp Neurol 1993, 52(4):351-360.
34. Franco I., Horowitz M., Grady R., et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol 2005, 173(1):221-225.
35. Cartwright P.C., Coplen D.E., Kogan B.A., et al. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol 2009, 182:1548-1554.
36. Buyse G., Waldeck K., Verpoorten C., et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998, 160(3 Pt 1):892-896.
37. Yarker Y.E., Goa K.L., FittonOxybutynin A. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995, 6(3):243-262.
38. O'Leary M., Erickson J.R., Smith C.P., et al. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003, 26(2):159-162.
39. Thuroff J.W., Bunke B., Ebner A., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991, 145(4):813-816. [discussion: 816-7].
40. Kennelly M.J., Lemack G.E., Foote J.E., et al. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009, 74:741-745.
41. Kim Y., Yoshimura N., Masuda H., et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 2005, 65(2):238-242.
42. De Wachter S., Wyndaele J.J. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 2003, 169(5):1892-1895.
43. Vaidyananthan S., Soni B.M., Brown E., et al. Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction. Spinal Cord 1998, 36(6):409-414.
44. Haferkamp A., Staehler G., Gerner H.J., et al. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 2000, 38(4):250-254.
45. Pannek J., Sommerfeld H.J., Botel U., et al. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 2000, 55(3):358-362.
46. Wan J., Rickman C. The durability of intravesical oxybutynin solutions over time. J Urol 2007, 178(4 Pt 2):1768-1770.
47. Nilvebrant L., Andersson K.E., Gillberg P.G., et al. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997, 327(2-3):195-207.
48. Ethans K.D., Nance P.W., Bard R.J., et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004, 27(3):214-218.
49. Nagels G, De DEyn P, Vleugels L, et al. A prospective randomized double blind cross-over dose titration study to evaluate the cognitive safety profile of tolterodine as compared to oxybutynin in multiple sclerosis patients with overactive bladder: a planned interim analysis [abstract 237]. Presented at the Annual ICS meeting, 2004. Available at: Accessed June 26, 2010. https://www.icsoffice.org/ASPNET_Membership/Membership/Abstracts/AbstractsSearch.aspx?EventID=42.
50. Reddy P.P., Borgstein N.G., Nijman R.J., et al. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol 2008, 4(6):428-433.
51. Mahanta K., Medhi B., Kaur B., et al. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. J Pediatr Urol 2008, 4(2):118-123.
52. Madersbacher H., Stohrer M., Richter R., et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995, 75(4):452-456.
53. Madersbacher H., Stohrer M., Richter R., et al. High-dose trospium chloride in therapy of detrusor hyperreflexia. Urologe A 1991, 30(4):260-263.
54. Menarini M., Del Popolo G., Di Benedetto P., et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?. Int J Clin Pharmacol Ther 2006, 44(12):623-632.
55. Chapple C.R. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 2004, 13(11):1493-1500.
56. Oki T., Sato S., Miyata K., et al. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol 2005, 145(2):219-227.
57. Herschorn S., Swift S., Guan Z., et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010, 105(1):58-66.
58. Madersbacher H., Murtz G., Alloussi S., et al. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int 2009, 103(6):776-781.
59. Grigoleit U., Murtz G., Laschke S., et al. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity-a retrospective study. Eur Urol 2006, 49(6):1114-1120. [discussion: 1120-1].
60. Djavan B., Chapple C., Milani S., et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004, 64(6):1081-1088.
61. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005, 95(7):1006-1012.
62. Consortium for Spinal Cord Medicine Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med 2006, 29(5):527-573.
63. Schwinn D.A. Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2000, 86(Suppl 2):11-20. [discussion: 20-2].
64. Price D.T., Schwinn D.A., Lomasney J.W., et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993, 150(2 Pt 1):546-551.
65. Forray C., Bard J.A., Wetzel J.M., et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol 1994, 45(4):703-708.
66. Walden P.D., Durkin M.M., Lepor H., et al. Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 1997, 157(3):1032-1038.
67. Malloy B.J., Price D.T., Price R.R., et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998, 160(3 Pt 1):937-943.
68. Smith M.S., Schambra U.B., Wilson K.H., et al. Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 1999, 63(2):254-261.
69. Restorick J.M., Mundy A.R. The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. Br J Urol 1989, 63(1):32-35.
70. Sun Y., Keay S., De Deyne P.G., et al. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol 2001, 166(5):1951-1956.
71. Sun Y., MaLossi J., Jacobs S.C., et al. Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia. Urology 2002, 60(2):351-356.
72. Kaplan P.E., Nanninga J.B. Reduction of bladder contractility after alpha-adrenergic blockade and after ganglionic blockade. Acta Neurol Scand 1979, 59(4):172-177.
73. Petersen T., Husted S.E., Sidenius P. Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability. Scand J Urol Nephrol 1989, 23(3):189-194.
74. Kakizaki H., Ameda K., Kobayashi S., et al. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol 2003, 10(11):576-581.
75. Abrams P., Amarenco G., Bakke A., et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003, 170(4 Pt 1):1242-1251.
76. Stankovich E.I., Borisov V.V., Demina T.L. Urologiia 2004, 4:48-51. [in Russian].
77. Perrigot M., Delauche-Cavallier M.C., Amarenco G., et al. Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study Group. Neurourol Urodyn 1996, 15(2):119-131.
78. Linsenmeyer T.A., Horton J., Benevento J. Impact of alpha1-blockers in men with spinal cord injury and upper tract stasis. J Spinal Cord Med 2002, 25(2):124-128.
79. O'Riordan J.I., Doherty C., Javed M., et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?. J Urol 1995, 153(4):1114-1116.
80. Krum H., Louis W.J., Brown D.J., et al. A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients. Clin Auton Res 1992, 2(2):83-88.
81. Chancellor M.B., Erhard M.J., Hirsch I.H., et al. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol 1994, 151(1):111-113.
82. Chancellor M.B., Anderson R.U., Boone T.B. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006, 85(6):536-545.
83. Vaidyanathan S., Soni B.M., Sett P., et al. Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and paediatric spinal cord injury patients manifesting recurrent dysreflexic episodes. Spinal Cord 1998, 36(11):761-770.
84. Yasuda K., Yamanishi T., Kawabe K., et al. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol 1996, 156(3):1125-1130.
85. Levin R.M., Staskin D.R., Wein A.J. Analysis of the anticholinergic and musculotropic effects of desmethylimipramine on the rabbit urinary bladder. Urol Res 1983, 11(6):259-262.
86. Maggi C.A., Borsini F., Lecci A., et al. Effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats. J Pharmacol Exp Ther 1989, 248(1):278-285.
87. Hoebeke P.B., Vande Walle J. The pharmacology of paediatric incontinence. BJU Int 2000, 86(5):581-589.
88. Dave S., Grover V.P., Agarwala S., et al. The role of imipramine therapy in bladder exstrophy after bladder neck reconstruction. BJU Int 2002, 89(6):557-560. [discussion: 560-1].
89. Puri A., Bhatnagar V., Grover V.P., et al. Urodynamics-based evidence for the beneficial effect of imipramine on valve bladders in children. Eur J Pediatr Surg 2005, 15(5):347-353.
90. Cole A.T., Fried F.A. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972, 107(1):44-45.
91. Owens R.G., Karram M.M. Comparative tolerability of drug therapies used to treat incontinence and enuresis. Drug Saf 1998, 19(2):123-139.
92. Smellie J.M., McGrigor V.S., Meadow S.R., et al. Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs. Arch Dis Child 1996, 75(1):62-66.
93. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006, 296(19):2319-2328.
94. McGuire E.J., Savastano J.A. Effect of Alpha-adrenergic blockade and anticholinergic agents on the decentralized primate bladder. Neurourol Urodyn 1985, 4:139-142.
95. Swierzewski S.J. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol 1994, 151(4):951.
96. Kaneko K., Fujinaga S., Ohtomo Y., et al. Combined pharmacotherapy for nocturnal enuresis. Pediatr Nephrol 2001, 16(8):662-664.
97. Cameron A.P., Clemens J.Q., Latini J.M., et al. Combination drug therapy improves compliance of the neurogenic bladder. J Urol 2009, 182(3):1062-1067.
98. Natalin R., Reis L.O., Alpendre C., et al. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol 2010, 28:79-85.
99. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology 2002, 59(5 Suppl 1):25-29.
100. Biers S.M., Reynard J.M., Brading A.F. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 2006, 98(6):1310-1314.
101. Drake M.J. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 2008, 13(3):431-446.
102. Szallasi A., Blumberg P.M. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain 1996, 68(2-3):195-208.
103. de Groat W.C. Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Paraplegia 1995, 33(9):493-505.
104. de Seze M., Wiart L., de Seze M.P., et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004, 171(1):251-255.
105. de Seze M., Wiart L., Joseph P.A., et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998, 17(5):513-523.
106. Giannantoni A., Di Stasi S.M., Stephen R.L., et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004, 172(1):240-243.
107. MacDonald R., Monga M., Fink H.A., et al. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 2008, 31(2):157-165.
108. Ford A.P., Gever J.R., Nunn P.A., et al. Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S132-S143.
109. Pannek J., Janek S., Sommerer F., et al. Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study. Spinal Cord 2009, 47(7):561-564.
110. Freeman R.M., Adekanmi O., Waterfield M.R., et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006, 17(6):636-641.
111. Chapple C.R., Radley S.C., Martin S.W., et al. Serotonin-induced potentiation of cholinergic responses to electrical field stimulation in normal and neurogenic overactive human detrusor muscle. BJU Int 2004, 93(4):599-604.
112. Sakakibara R., Ito T., Uchiyama T., et al. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int 2008, 81(3):335-339.
113. Elzayat E.A., Campeau L., Karsenty G., et al. Effect of antiepileptic agent, levetiracetam, on urodynamic parameters and neurogenic bladder overactivity in chronically paraplegic rats. Urology 2009, 73(4):922-927.
114. Carbone A., Palleschi G., Conte A., et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 2006, 29(4):206-214.
115. Tanaka I., Nagase K., Tanase K., et al. Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors. J Urol 2010, 183(2):786-792.
116. Sasatomi K., Hiragata S., Miyazato M., et al. Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology 2008, 72(3):696-700.
117. Ogawa T., Sasatomi K., Hiragata S., et al. Therapeutic effects of endothelin-A receptor antagonist on bladder overactivity in rats with chronic spinal cord injury. Urology 2008, 71(2):341-345.
118. Miyazato M., Sasatomi K., Hiragata S., et al. GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord injured rats. J Urol 2008, 179(3):1178-1183.